Medgenics Inc

Medgenics to present poster at ESGCT Congress

RNS Number : 2206R
Medgenics Inc
23 October 2013







Press Release

23 October 2013



Medgenics To Present Poster at European Society of Gene and Cell Therapy Congress to Highlight Results from Second-Generation Viral Vector


Medgenics, Inc. (NYSE MKT: MDGN and AIM: MEDU, MEDG) (the "Company"), the developer of a novel technology for the sustained production and delivery of therapeutic proteins in patients using their own tissue, announces that a poster highlighting the Company's second-generation EPODURE Biopump™ will be presented at the European Society of Gene and Cell Therapy Congress, taking place in Madrid October 25-28.


Posters will be showcased in Poster Reception Halls A-C November 1-3 and will be available for viewing from 9:30 a.m. to 2:30 p.m. local time.  Poster presentations will take place from 10:00 a.m. to 12:00 p.m. The following Medgenics' poster will be presented during Poster Session B  on Sunday, October  27:


·      "Second generation EPODURE Biopumpmarkedly extends duration of EPO delivery in mice, could prolong therapeutic effect in patients," by Miari, et. al. Poster Number P146.


EPODURE is an autologous dermal Biopump capable of the sustained production of therapeutic erythropoietin ("EPO") in the body using a small tissue explant from the patient's own skin and processed to continuously produce EPO. Each EPODURE Biopump is subsequently implanted subcutaneously into the patient aiming to provide continuous delivery of EPO.


About The European Society of Gene and Cell Therapy (ESGCT)

The European Society of Gene and Cell Therapy (ESGCT) promotes basic and clinical research in gene therapy, cell therapy and genetic vaccines by facilitating education, the exchange of information and technology and by serving as a professional adviser to stakeholder communities and regulatory bodies in Europe.


About Medgenics

Medgenics is developing and commercializing Biopump™, a proprietary tissue-based platform technology for the sustained production and delivery of therapeutic proteins using the patient's own tissue for the treatment of a range of chronic diseases including anemia and hepatitis, among others.  For more information, please visit


Forward-looking Statements

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and as that term is defined in the Private Securities Litigation Reform Act of 1995, which include all statements other than statements of historical fact, including (without limitation) those regarding the Company's financial position, its development and business strategy, its product candidates and the plans and objectives of management for future operations. The Company intends that such forward-looking statements be subject to the safe harbors created by such laws. Forward-looking statements are sometimes identified by their use of the terms and phrases such as "estimate," "project," "intend," "forecast," "anticipate," "plan," "planning, "expect," "believe," "will," "will likely," "should," "could," "would," "may" or the negative of such terms and other comparable terminology. All such forward-looking statements are based on current expectations and are subject to risks and uncertainties. Should any of these risks or uncertainties materialize, or should any of the Company's assumptions prove incorrect, actual results may differ materially from those included within these forward-looking statements. Accordingly, no undue reliance should be placed on these forward-looking statements, which speak only as of the date made. The Company expressly disclaims any obligation or undertaking to disseminate any updates or revisions to any forward-looking statements contained herein to reflect any change in the Company's expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based. As a result of these factors, the events described in the forward-looking statements contained in this release may not occur.




Anne Marie Fields,

[email protected]




Abchurch Communications

Joanne Shears / Jamie Hooper / Harriet Rae

[email protected]


+44 207 398 7718


Oriel Securities (NOMAD & Joint Broker)

Jonathan Senior / Giles Balleny


+44 207 710 7617 


SVS Securities plc (Joint Broker)

Alex Brearley


+44 203 700 0100




This information is provided by RNS
The company news service from the London Stock Exchange